Sentences with phrase «at price action over»

Go back and look at price action over the past two weeks and see if you can determine if support and resistance levels the past two to three days can be verified.

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Because of the current pullback to the 10 - week MA, we expect the price action to hold at or around this level over the next week or two before the uptrend resumes.

You will learn over time that price action is a picture of price at it's current state versus historical indicators such as the MACD, RSI or other common technical indicators.

Our stop loss on this setup would be around 100 pips and the upside potential would be over 300 points, this is how professional traders look at the market; analyze levels, look at the price action signals, nice tight stop and nice wide profit target.

«The price action since the FOMC statement indicates a real division of opinion in markets over the US dollar outlook,» said Sean Callow, a strategist at Westpac.

Farmers For Action (FFA) demonstrated and created blockades at Arla Foods UK and Muller Wiseman Dairies processing facilities last week, in its latest attempt to bring an end to its long - running dispute with processors over farm gate milk prices.

Representing Mr Mitchell at the High Court, James Price QC today opened the Sutton Coldfield MP's libel action against News Group Newspapers (NGN) over the story.

Smashwords Read an Ebook Week Catalog - This is the hub of the action, where you find over 75,000 multi-format books regularly priced at free every day, and thousands more that are free or deep - discounted exclusively at Smashwords during Read an Ebook Week only.

Go over the price action while you were at work, see what happened.

You are going over what happened while you were sleeping, looking at how the price action of your favorite markets reacted near key chart levels or if any price action setups formed in - line with the trend.

Our stop loss on this setup would be around 100 pips and the upside potential would be over 300 points, this is how professional traders look at the market; analyze levels, look at the price action signals, nice tight stop and nice wide profit target.

If you actually do this with discipline, by only taking obvious price action setups and rigidly implementing a risk reward of at last 1 to 2, you will become profitable over a series of trades.

When we combine this knowledge of the power of risk to reward with a high - probability edge like price action, what we have is a professional money management and trading strategy, which when combined with the proper education and discretion will make money over a series of at least 20 trades or more.

Let's take a look at the way many traders try to trade with lagging and leading indicators all over their charts, and then let's compare this to trading with nothing but a plain vanilla price chart and price action.

By taking a look at the general direction of the price action in a market over the last 3 month to 1 year, we can easily see whether it's generally trending up, down or even sideways.

Price action over the last four days can be seen as a â $ ˜ pennantâ $ ™ suggesting another burst higher this week with a measured target of at least 1.4720, maybe 1.4825.

Soon the price action, or at some point the price action takes over and you want to buy three houses and five houses and you want to buy with nothing down and you want to agree to payments that you can't make and all of that sort of thing because it doesn't make any difference, it's going to be worth more next year.

February 2004 by Wayne Thorp A closer look at our top - performing screen over the long term, based on Martin Zweig's approach to identifying stocks that have strong earnings growth and price action, and selling at reasonable price - earnings ratios.

AAII Stock Ideas The Zweig Approach: Growth Stocks That Can Keep Pace A closer look at our top - performing screen over the long term, based on Martin Zweig's approach to identifying stocks that have strong earnings growth and price action, and selling at reasonable price - earnings ratios.

A closer look at our top - performing screen over the long term, based on Martin Zweig's approach to identifying stocks that have strong earnings growth and price action, and selling at reasonable price - earnings ratios.

While the Competition Bureau has announced a deal aimed at lowering the price of electronic books, a class action over the practices of Apple Inc. and several major publishers will go ahead, according to a lawyer involved in the case.

The media has been talking a lot about the explosive price action over the past year, but they're not doing a great job at educating people how all of it works and what amazing innovations are being created.